Ki67 protein: the immaculate deception?

10.1111/j.1365-2559.1990.tb00788.x

10.1002/ijc.2910310104

10.1002/path.1711680404

10.1002/hep.510260307

Gerlach C, 1997, Ki‐67 immunoexpression is a robust marker of proliferative cells in the rat, Lab. Invest., 77, 697

10.1002/(sici)1097-4652(200003)182:3<311::aid-jcp1>3.0.co;2-9

10.1006/excr.2000.4888

10.1083/jcb.123.3.513

10.1016/S0968-0004(00)89072-6

10.1242/jcs.92.1.123

10.1002/(sici)1096-9896(200004)190:5<537::aid-path577>3.0.co;2-w

10.1111/j.1365-2184.1996.tb00984.x

10.1002/cyto.990130508

10.1002/(sici)1097-4644(20000315)76:4<596::aid-jcb8>3.0.co;2-n

10.1242/jcs.112.15.2463

10.1242/jcs.109.1.143

10.1023/A:1009210206855

10.1007/s002590050394

10.1136/jcp.47.11.1010

10.1046/j.1365-2559.1999.00862.x

10.1002/(SICI)1097-0045(19991101)41:3<166::AID-PROS3>3.0.CO;2-E

10.1016/s0090-4295(99)00107-7

Paradiso A, 1999, Metastatic site and p53 primary tumor expression in previously untreated stage IV breast cancer patients, Anticancer Res., 19, 4523

10.1002/1097-0142(19951015)76:8<1313::AID-CNCR2820760804>3.0.CO;2-1

10.1016/S0140-6736(87)90977-9

10.1002/1097-0142(19921101)70:9<2342::AID-CNCR2820700922>3.0.CO;2-6

10.1002/path.1711540305

Grogan TM, 1988, et al. Independent prognostic significance of a nuclear proliferation antigen in diffuse large cell lymphomas as determined by the monoclonal antibody Ki‐67, Blood, 71, 1157, 10.1182/blood.V71.4.1157.1157

10.1159/000205957

10.1007/BF00594196

10.1046/j.1365-2141.1999.01417.x

10.1002/(SICI)1097-0142(19960315)77:6<1180::AID-CNCR26>3.0.CO;2-X

10.1038/sj.bjc.6690091

Kimura T, 2000, Clinical significance of MUC1 and E‐cadherin expression, cellular proliferation, and angiogenesis at the deepest invasive portion of colorectal cancer, Int. J. Oncol., 16, 55

Ofner D, 1996, MIB1 in colorectal carcinomas: its evaluation by three different methods reveals lack of prognostic significance, Anal. Cell Pathol., 12, 61

10.1007/BF02050423

10.1038/bjc.1995.497

10.1002/(sici)1097-0215(19970822)74:4<433::aid-ijc12>3.0.co;2-a

Weikel W, 1995, Growth fractions (Ki‐67) in primary breast cancers, with particular reference to node‐negative tumors, Cancer Detect. Prev., 19, 446

10.1002/(sici)1096-9896(199901)187:2<207::aid-path223>3.0.co;2-u

10.1200/JCO.1998.16.2.470

Domagala W, 1996, Prognostic significance of tumor cell proliferation rate as determined by the MIB‐1 antibody in breast carcinoma: its relationship with vimentin and p53 protein, Clin. Cancer Res., 2, 147

10.1007/BF01806492

10.1038/bjc.1998.515

10.1002/path.1711760405

10.1093/ajcp/104.1.42

10.1038/bjc.1995.30

10.1002/(SICI)1097-0215(19980220)79:1<27::AID-IJC6>3.0.CO;2-Y

10.1002/(sici)1097-0215(19960422)69:2<135::aid-ijc12>3.3.co;2-q

Veronese SM, 1995, Comparative prognostic value of Ki‐67 and MIB‐1 proliferation indices in breast cancer, Anticancer Res., 15, 2717

10.1002/(sici)1096-9896(199802)184:2<130::aid-path19>3.3.co;2-n

Midulla C, 1999, Immunohistochemical expression of p53, nm23‐HI, Ki67 and DNA ploidy: correlation with lymph node status and other clinical pathologic parameters in breast cancer, Anticancer Res., 19, 4033

10.1038/bjc.1989.200

Locker AP, 1992, Ki67 immunoreactivity in breast carcinoma: relationships to prognostic variables and short term survival, Eur. J. Surg. Oncol., 18, 224

Gottardi O, 1992, [Clinical and prognostic usefulness of Ki67 determination in breast carcinoma], Pathologica, 84, 15

10.1006/gyno.1995.1104

10.1016/s0968-4328(99)00071-2

10.1200/JCO.1999.17.10.3058

10.1038/bjc.1997.261

Rohr UP, 1998, [Significance of differential nuclear expression of Ki‐67 in adult soft tissue sarcomas], Verh Dtsch Ges. Pathol., 82, 345

10.1080/000164700753767944

10.1038/sj.bjc.6690151

Rudolph P, 1998, Comparative analysis of prognostic indicators for sarcomas of the soft parts and the viscerae, Verh. Dtsch Ges. Pathol., 82, 246

Stefanou DG, 1998, p53/MDM‐2 immunohistochemical expression correlated with proliferative activity in different subtypes of human sarcomas: a ten‐year follow‐up study, Anticancer Res., 18, 4673

10.1002/(sici)1097-0142(19980801)83:3<490::aid-cncr18>3.3.co;2-y

10.1200/JCO.1997.15.10.3249

Brinck U, 1995, P‐53 positivity and high proliferative index: factors of bad prognosis in malignant fibrous histiocytomas, In Vivo, 9, 475

10.1111/j.1699-0463.1995.tb01437.x

10.1002/1097-0142(19950201)75:3<806::AID-CNCR2820750310>3.0.CO;2-S

10.1111/j.1699-0463.1994.tb05253.x

Rudolph P, 1997, Prognostic relevance of a novel proliferation marker, Ki‐S11, for soft‐tissue sarcoma. A multivariate study, Am. J. Pathol., 150, 1997

Golouh R, 1996, Predictive value of proliferation‐related markers, p53, and DNA ploidy for survival in patients with soft tissue spindle‐cell sarcomas, Mod. Pathol., 9, 919

O'Reilly PE, 1997, p53, proliferating cell nuclear antigen, and Ki‐67 expression in extrauterine leiomyosarcomas, Mod. Pathol., 10, 91

10.1038/sj.bjc.6690801

Hayashi Y, 1993, Cell‐cycle analysis detecting endogenous nuclear antigens: comparison with BrdU‐in vivo labeling and an application to lung tumors, Acta Pathol. Jpn, 43, 313

10.1016/0959-8049(93)90387-U

10.1001/archsurg.1993.01420240090017

Harpole DH Jr, 1995, A prognostic model of recurrence and death in stage I non‐small cell lung cancer utilizing presentation, histopathology, and oncoprotein expression, Cancer Res., 55, 51

10.1002/(SICI)1096-9896(199604)178:4<402::AID-PATH498>3.0.CO;2-5

10.1016/S0344-0338(99)80050-8

Soomro IN, 1998, Predicting prognosis in lung cancer: use of proliferation marker, Ki67 monoclonal antibody, J. Pak. Med. Assoc., 48, 66

10.1016/S0360-3016(97)00898-5

Wang J, 1997, [Preliminary study on relationship among apoptosis and related gene, prognosis of lung cancer], Zhonghua Jie He He Hu Xi Za Zhi, 20, 141

Wang D, 1997, [Multivariate analysis of prognostic factors in non‐small cell lung cancer], Zhonghua Yi Xue Za Zhi, 77, 497

10.1038/bjc.1996.466

10.1016/S0022-5223(99)70294-1

Enestrom S, 1998, Ki‐67 antigen expression as a prognostic factor in primary and recurrent astrocytomas, Neurochirurgie, 44, 25

10.1002/(SICI)1097-0142(19980615)82:12<2459::AID-CNCR21>3.0.CO;2-N

Kirkegaard LJ, 1998, Image cytometric measurement of nuclear proliferation markers (MIB‐1, PCNA) in astrocytomas. Prognostic significance, Am. J. Clin. Pathol., 109, 69, 10.1093/ajcp/109.1.69

10.3171/jns.1997.86.1.0121

10.1002/(sici)1097-0142(19960115)77:2<373::aid-cncr21>3.3.co;2-7

10.1136/jnnp.59.4.413

10.1002/path.1711740407

10.1038/bjc.1992.273

10.1016/S0090-3019(97)00312-1

10.1097/00006123-199804000-00021

Madsen C, 1997, Ki‐67 immunoreactivity in meningiomas—determination of the proliferative potential of meningiomas using the monoclonal antibody Ki‐67, Clin. Neuropathol., 16, 137

10.1002/1097-0142(19941215)74:12<3176::AID-CNCR2820741217>3.0.CO;2-N

10.1016/S0046-8177(98)90224-6

10.1023/A:1005946001915

10.1046/j.1365-2990.1998.00150.x

10.1002/(sici)1097-0142(19990515)85:10<2249::aid-cncr21>3.0.co;2-5

10.1006/gyno.1995.1179

10.1002/1097-0142(19931015)72:8<2401::AID-CNCR2820720818>3.0.CO;2-D

Nanjyo T, 1994, [The correlation between the therapeutic effects and the tumor growth fraction in cervical cancer and ovarian cancer], Nippon Sanka Fujinka Gakkai Zasshi, 46, 27

10.1002/(SICI)1097-0142(19970201)79:3<513::AID-CNCR13>3.0.CO;2-6

10.1006/gyno.1999.5663

10.1016/S0959-8049(97)00161-5

10.1006/gyno.1997.4835

10.1002/(sici)1097-0215(19970822)74:4<421::aid-ijc10>3.0.co;2-c

10.1097/00004347-199601000-00004

10.1016/0167-8140(95)01622-N

10.1038/bjc.1992.167

10.1093/ajcp/109.2.163

10.1016/S0022-5347(01)66162-7

10.1097/00005392-199805000-00054

Bai XZ, 1999, Prognostic markers in clinically localised prostate cancer, Int. J. Oncol., 14, 785

10.1016/S0046-8177(98)90199-X

10.1093/ajcp/110.4.443

10.1111/j.1440-1827.1998.tb03826.x

Aaltomaa S, 1997, Value of Ki‐67 immunolabelling as a prognostic factor in prostate cancer, Eur. Urol., 32, 410, 10.1159/000480798

Stattin P., 1997, Prognostic factors in prostate cancer, Scand. J. Urol. Nephrol. Suppl., 185, 1

10.1016/S0039-6060(96)80283-2

10.1016/S0022-5347(01)65703-3

10.1002/(SICI)1096-9896(199604)178:4<437::AID-PATH484>3.3.CO;2-W

10.1002/pros.2990210108

10.1111/j.1464-410X.1993.tb06466.x

10.1002/1097-0142(19910615)67:12<3065::AID-CNCR2820671222>3.0.CO;2-U

Sadi MV, 1991, Androgen receptors and growth fraction in metastatic prostate cancer as predictors of time to tumour progression after hormonal therapy, Cancer Surv., 11, 195

10.1016/S0022-5347(01)65329-1

10.1002/(SICI)1096-9098(199801)67:1<33::AID-JSO7>3.0.CO;2-N

10.1002/(sici)1097-0142(19980101)82:1<168::aid-cncr21>3.0.co;2-#

10.1002/(SICI)1097-0215(19990621)84:3<225::AID-IJC5>3.0.CO;2-A

10.1046/j.1440-1746.1999.01805.x

10.1002/(sici)1097-0215(19991222)84:6<545::aid-ijc1>3.0.co;2-2

10.1002/1097-0142(19921201)70:11<2602::AID-CNCR2820701106>3.0.CO;2-W

10.1002/(SICI)1097-0142(19960115)77:2<255::AID-CNCR6>3.0.CO;2-L

10.1111/j.1699-0463.1997.tb05078.x

10.1002/hep.510280411

Mairinger T, 1999, Mean weighted nuclear volumes in colonic adenocarcinomas. Evaluation of prognostic significance, Anal. Quant. Cytol. Histol., 21, 194

10.1016/S0190-9622(97)80121-1

Korabiowska M, 2000, Proliferative activity in the progression of pigmented skin lesions, diagnostic and prognostic significance, Anticancer Res., 20, 1781

10.1002/(sici)1096-9896(200004)190:5<545::aid-path549>3.3.co;2-j

Heatley MK., 1998, What is the value of proliferation markers in the normal and neoplastic cervix, Histol. Histopathol., 13, 249

10.1046/j.1365-2559.2000.00934.x

10.1016/S0046-8177(98)90014-4

10.1034/j.1600-0560.2000.027004169.x